Department of Paediatrics, Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong
WM But (畢慧文) MBBS, FRCP
WY Tse (謝詠儀) MBBS, FRCP
Department of Paediatrics & Adolescent Medicine, Tseung Kwan O Hospital, 2 Po Ling Lane, Tseung Kwan O, N.T., Hong Kong
KF Huen (禤桂芬) FHKCPaed, FRCPCH
Department of Paediatrics & Adolescent Medicine, Caritas Medical Centre, 111 Wing Hong Street, Shamshuipo, Kowloon, Hong Kong
CY Lee (李靜賢) FHKCPaed, FRCP
Department of Paediatrics & Adolescent Medicine, Kwong Wah Hospital, 25 Waterloo Road, Kowloon, Hong Kong
YY Lam (林琬瑜) FHKCPaed, FHKAM(Paed)
Private Practice, Specialist in Paediatrics, Hong Kong
CM Yu (余則文) FHKAM(Paed), FRCP
Correspondence to: Dr CY Lee
Received February 1, 2012
Since 1978, Growth hormone (GH) has been used to treat patients with GH deficiency in Hong Kong. In 1998, the Hospital Authority expanded the use of GH in children with Turner syndrome and chronic renal failure before transplantation. Two additional indications for GH treatment, Prader-Willi syndrome and short stature homeobox-containing gene disorders have been approved in 2012. The objective of this paper is to discuss the recommendations of GH treatment for children and adolescents with these conditions in Hong Kong.
